EGF stimulates cyclooxygenase-2 expression through the STAT5 signaling pathway in human lung adenocarcinoma A549 cells

International Journal of Oncology

Volumn 39, Issue 2, 2011, Pages 383-391

  Cao, Shouqiang ^a   Yan, Yubo ^a   Zhang, Xiangyu ^a   Zhang, Kai ^a   Liu, Cheng ^a   Zhao, Guibin ^a   Han, Jingquan ^a   Dong, Qing ^a   Shen, Baozhong ^a   Wu, Anhua ^b   Cui, Jian ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

A549; Cyclooxygenase 2; Epidermal growth factor; Lung adenocarcinoma; STAT5

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; SMALL INTERFERING RNA; STAT5 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DNA-BINDING PROTEINS; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR;

EID: 79959968633     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1053     Document Type: Article

References (54)

1. Alroy I and Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410: 83-86, 1997. (Pubitemid 27283389)
2. Riese DJ II and Stern DF: Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20: 41-48, 1998.
3. De Luca A, Carotenuto A, Rachiglio A, et al: The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214: 559-567, 2008. (Pubitemid 351224199)
4. Bonanno L, Schiavon M, Nardo G, et al: Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Res 30: 5121-5128, 2010.
5. Gu L, Vogiatzi P, Puhr M, et al: Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer 17: 481-493, 2010.
6. Sung YH, Park J, Choi B, et al: Hematopoietic malignancies associated with increased Stat5 and Bcl-x(L) expressions in Ink4a/Arf-deficient mice. Mech Ageing Dev 126: 732-739, 2005. (Pubitemid 40693297)
7. Wagner KU and Rui H: Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. J Mammary Gland Biol Neoplasia 13: 93-103, 2008.
8. Smith WL, DeWitt DL and Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182, 2000.
9. Morita I: Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 68-69: 165-175, 2002.
10. Takeuchi K, Tanaka A, Suzuki K and Mizoguchi H: Gastrointestinal sparing anti-inflammatory drugs - effects on ulcerogenic and healing responses. Curr Pharm Des 7: 49-69, 2001. (Pubitemid 32409707)
11. Schwab JM, Schluesener HJ, Meyermann R and Serhan CN: COX-3 the enzyme and the concept: steps towards highly specialized pathways and precision therapeutics? Prostaglandins Leukot Essent Fatty Acids 69: 339-343, 2003.
12. Husvik C, Bryne M and Halstensen TS: Epidermal growth factor-induced cyclooxygenase-2 expression in oral squamous cell carcinoma cell lines is mediated through extracellular signal-regulated kinase 1/2 and p38 but is Src and nuclear factor-kappa B independent. Eur J Oral Sci 117: 528-535, 2009.
13. Seo M and Juhnn YS: Gq protein mediates UVB-induced cyclooxygenase-2 expression by stimulating HB-EGF secretion from HaCaT human keratinocytes. Biochem Biophys Res Commun 393: 190-195, 2010.
14. Rasanen K and Vaheri A: TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes. J Dermatol Sci 58: 97-104, 2010.
15. Bage T, Lindberg J, Lundeberg J, Modeer T and Yucel-Lindberg T: Signal pathways JNK and NF-kappaB, identified by global gene expression profiling, are involved in regulation of TNFalpha-induced mPGES-1 and COX-2 expression in gingival fibroblasts. BMC Genomics 11: 241, 2010.
16. Bradbury DA, Newton R, Zhu YM, et al: Effect of bradykinin, TGF-beta1, IL-1beta, and hypoxia on COX-2 expression in pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 283: L717-L725, 2002.
17. Chan E, Lafleur B, Rothenberg ML, et al: Dual Blockade of the EGFR and COX-2 Pathways: A Phase II Trial of Cetuximab and Celecoxib in Patients With Chemotherapy Refractory Metastatic Colorectal Cancer. Am J Clin Oncol: Jan 6, 2011 (Epub ahead of print).
18. Liu X, Li P, Zhang ST, You H, Jia JD and Yu ZL: COX-2 mRNA expression in esophageal squamous cell carcinoma (ESCC) and effect by NSAID Dis Esophagus 21: 9-14, 2008.
19. Blanco A, Habib A, Levy-Toledano S and Maclouf J: Involvement of tyrosine kinases in the induction of cyclo-oxygenase-2 in human endothelial cells. Biochem J 312 (Pt 2): 419-423, 1995. (Pubitemid 26002205)
20. Allport VC, Slater DM, Newton R and Bennett PR: NF-kappaB and AP-1 are required for cyclo-oxygenase 2 gene expression in amnion epithelial cell line (WISH). Mol Hum Reprod 6: 561-565, 2000. (Pubitemid 30365803)
21. Chen LC, Chen BK and Chang WC: Activating protein 1-mediated cyclooxygenase-2 expression is independent of N-terminal phosphorylation of c-Jun. Mol Pharmacol 67: 2057-2069, 2005.
22. Fan XM, Wong BC, Lin MC, et al: Interleukin-1beta induces cyclo-oxygenase-2 expression in gastric cancer cells by the p38 and p44/42 mitogen-activated protein kinase signaling pathways. J Gastroenterol Hepatol 16: 1098-1104, 2001. (Pubitemid 32990104)
23. Jung YJ, Isaacs JS, Lee S, Trepel J and Neckers L: IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 17: 2115-2117, 2003.
24. Yamashita H, Iwase H, Toyama T and Fujii Y: Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells. Oncogene 22: 1638-1652, 2003. (Pubitemid 36408179)
25. Wu A, Ericson K, Chao W and Low WC: NFAT and AP1 are essential for the expression of a glioblastoma multiforme related IL-13Ra2 transcript. Cell Oncol 32: 313-329, 2010.
26. Darnell JE Jr: STATs and gene regulation. Science 277: 1630-1635, 1997.
27. Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene 19: 2474-2488, 2000.
28. Niu G, Wright KL, Huang M, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008, 2002.
29. Lin TS, Mahajan S and Frank DA: STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 19: 2496-2504, 2000. (Pubitemid 30339205)
30. Li H, Ahonen TJ, Alanen K, et al: Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 64: 4774-4782, 2004. (Pubitemid 38924520)
31. Grandis JR, Drenning SD, Zeng Q, et al: Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 97: 4227-4232, 2000. (Pubitemid 30226115)
32. Xi S, Zhang Q, Dyer KF, et al: Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem 278: 31574-31583, 2003. (Pubitemid 37048335)
33. Song L, Turkson J, Karras JG, Jove R and Haura EB: Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22: 4150-4165, 2003. (Pubitemid 36876236)
34. Klampfer L: Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 6: 107-121, 2006.
35. Vinkemeier U: Getting the message across, STAT! Design principles of a molecular signaling circuit. J Cell Biol 167: 197-201, 2004.
36. Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng KS and Huang CY: IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 289: L446-L453, 2005.
37. Ihle JN: The Stat family in cytokine signaling. Curr Opin Cell Biol 13: 211-217, 2001.
38. Rui H, Djeu JY, Evans GA, Kelly PA and Farrar WL: Prolactin receptor triggering. Evidence for rapid tyrosine kinase activation. J Biol Chem 267: 24076-24081, 1992. (Pubitemid 23088228)
39. Rui H, Lebrun JJ, Kirken RA, Kelly PA and Farrar WL: JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization. Endocrinology 135: 1299-1306, 1994. (Pubitemid 24307502)
40. Mirmohammadsadegh A, Hassan M, Bardenheuer W, et al: STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol 126: 2272-2280, 2006. (Pubitemid 44413174)
41. Mui AL, Wakao H, O'Farrell AM, Harada N and Miyajima A: Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J 14: 1166-1175, 1995.
42. Lai CF, Ripperger J, Morella KK, et al: STAT3 and STAT5B are targets of two different signal pathways activated by hematopoietin receptors and control transcription via separate cytokine response elements. J Biol Chem 270: 23254-23257, 1995.
43. Novak U, Mui A, Miyajima A and Paradiso L: Formation of STAT5-containing DNA binding complexes in response to colony-stimulating factor-1 and platelet-derived growth factor. J Biol Chem 271: 18350-18354, 1996. (Pubitemid 26322688)
44. Wakao H, Harada N, Kitamura T, Mui AL and Miyajima A: Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways. EMBO J 14: 2527-2535, 1995.
45. Gouilleux F, Pallard C, Dusanter-Fourt I, et al: Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity. EMBO J 14: 2005-2013, 1995.
46. Pallard C, Gouilleux F, Benit L, et al: Thrombopoietin activates a STAT5-like factor in hematopoietic cells. EMBO J 14: 2847-2856, 1995.
47. Ruff-Jamison S, Chen K and Cohen S: Epidermal growth factor induces the tyrosine phosphorylation and nuclear translocation of Stat 5 in mouse liver. Proc Natl Acad Sci USA 92: 4215-4218, 1995.
48. Gouilleux F, Wakao H, Mundt M and Groner B: Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J 13: 4361-4369, 1994. (Pubitemid 24295208)
49. Kazansky AV, Raught B, Lindsey SM, Wang YF and Rosen JM: Regulation of mammary gland factor/Stat5a during mammary gland development. Mol Endocrinol 9: 1598-1609, 1995.
50. Wang D, Stravopodis D, Teglund S, Kitazawa J and Ihle JN: Naturally occurring dominant negative variants of Stat5. Mol Cell Biol 16: 6141-6148, 1996. (Pubitemid 26360974)
51. Yamashita H, Nevalainen MT, Xu J, et al: Role of serine phosphorylation of Stat5a in prolactin-stimulated beta-casein gene expression. Mol Cell Endocrinol 183: 151-163, 2001. (Pubitemid 32938521)
52. Beuvink I, Hess D, Flotow H, Hofsteenge J, Groner B and Hynes NE: Stat5a serine phosphorylation. Serine 779 is constitutively phosphorylated in the mammary gland, and serine 725 phosphorylation influences prolactin-stimulated in vitro DNA binding activity. J Biol Chem 275: 10247-10255, 2000. (Pubitemid 30202081)
53. Yamashita H, Xu J, Erwin RA, Farrar WL, Kirken RA and Rui H: Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells. J Biol Chem 273: 30218-30224, 1998. (Pubitemid 28545486)
54. Richardson CM, Richardson D, Swinson DE, Swain WA, Cox G and O'Byrne KJ: Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer. Lung Cancer 48: 47-57, 2005. (Pubitemid 40380999)